Literature DB >> 31729037

Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.

Ian S Reynolds1,2, Emer O'Connell1,2, Michael Fichtner2, Deborah A McNamara1,3, Elaine W Kay4, Jochen H M Prehn2,5, Simon J Furney2,5,6, John P Burke1.   

Abstract

BACKGROUND AND OBJECTIVES: Mucinous adenocarcinoma is a distinct subtype of colorectal cancer (CRC) with a worse prognosis when compared with non-mucinous adenocarcinoma. The aim of this study was to compare somatic mutations and copy number alteration (CNA) between mucinous and non-mucinous CRC.
METHODS: Data from The Cancer Genome Atlas-colon adenocarcinoma and rectum adenocarcinoma projects were utilized. Mucinous and non-mucinous CRC were compared with regard to microsatellite status, overall mutation rate, the most frequently mutated genes, mutations in genes coding for mismatch repair (MMR) proteins and genes coding for mucin glycoproteins. CNA analysis and pathway analysis was undertaken.
RESULTS: Mucinous CRC was more likely to be microsatellite instability-high (MSI-H) and hypermutated. When corrected for microsatellite status the single-nucleotide variation and insertion-deletion rate was similar between the two cohorts. Mucinous adenocarcinoma was more likely to have mutations in genes coding for MMR proteins and mucin glycoproteins. Pathway analysis revealed further differences between the two histological subtypes in the cell cycle, RTK-RAS, transforming growth factor-β, and TP53 pathways.
CONCLUSIONS: Mucinous CRC has some distinct genomic aberrations when compared with non-mucinous adenocarcinoma, many of which are driven by the increased frequency of MSI-H tumors. These genomic aberrations may play an important part in the difference seen in response to treatment and prognosis in mucinous adenocarcinoma.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  colorectal cancer; mucinous adenocarcinoma; oncogenetics

Mesh:

Substances:

Year:  2019        PMID: 31729037     DOI: 10.1002/jso.25764

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Combined fibrinogen-to-pre-albumin ratio and carbohydrate antigen 19-9 score is a promising metric to predict progression of metastatic colorectal mucinous adenocarcinoma.

Authors:  Yu-Cui Liao; Ming Fu; Xue-Feng Wang; Xue-Xin Cheng
Journal:  J Clin Lab Anal       Date:  2021-03-18       Impact factor: 2.352

2.  Unusual Presentation of Carcinoma Rectum-a Case Report.

Authors:  Someswara Rao Meegada; Kishore V Alapati; Mathai Varughese; Chinnaya Parimi
Journal:  Indian J Surg Oncol       Date:  2021-04-29

3.  Native T1 mapping for differentiating the histopathologic type, grade, and stage of rectal adenocarcinoma: a pilot study.

Authors:  Juan Li; Xuemei Gao; Marcel Dominik Nickel; Jingliang Cheng; Jinxia Zhu
Journal:  Cancer Imaging       Date:  2022-06-17       Impact factor: 5.605

4.  Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden.

Authors:  Hong Yuan; Jun Ji; Min Shi; Yan Shi; Jing Liu; Junwei Wu; Chen Yang; Wenqi Xi; Qingyuan Li; Wei Zhu; Jingjie Li; Xiaoli Gong; Jun Zhang
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  Low-kilovolt x-ray intraoperative radiotherapy for pT3 locally advanced colon cancer: a single-institution retrospective analysis.

Authors:  Li Ma; Junhao Qiang; Heliang Yin; Lin Lin; Yan Jiao; Changying Ma; Xinwei Li; Li Dong; Jinglin Cui; Dongmei Wei; Ankur M Sharma; David L Schwartz; Weikuan Gu; Hong Chen
Journal:  World J Surg Oncol       Date:  2020-06-17       Impact factor: 2.754

6.  Identification of differentially expressed genes between mucinous adenocarcinoma and other adenocarcinoma of colorectal cancer using bioinformatics analysis.

Authors:  Xue Zhang; Jing Zuo; Long Wang; Jing Han; Li Feng; Yudong Wang; Zhisong Fan
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

7.  Amide Proton Transfer Weighted and Intravoxel Incoherent Motion Imaging in Evaluation of Prognostic Factors for Rectal Adenocarcinoma.

Authors:  Juan Li; Liangjie Lin; Xuemei Gao; Shenglei Li; Jingliang Cheng
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.